Holen Sie sich die Stockscreener-App
0.9842
2.07%
-0.0208
Handel nachbörslich:
.98
-0.0042
-0.43%
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
Q1 Earnings Forecast for IO Biotech Issued By HC Wainwright - Defense World
Globus Medical acquires Nevro Corp. - Medical Buyer
Top 5 CRISPR Companies To Invest In (April 2025) - Securities.io
IO Biotech (NASDAQ:IOBT) Given “Buy” Rating at HC Wainwright - Defense World
IO Biotech secures over 400 million dkk in new capital - Dansk Industri
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
IO Biotech Announces Acceptance Of Abstracts To Be Presented At The 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener
Cancer Vaccine Breakthrough: IO Biotech Reveals Phase 3 Melanoma Data at AACR 2025 - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Globe and Mail
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 - The Manila Times
IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025 - TradingView
Fast Company Names IO Biotech Top 10 Innovator for Cancer Vaccine Breakthrough - StockTitan
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times
Partex and Fortress Biotech Announce Strategic - GlobeNewswire
IO Biotech (NASDAQ:IOBT) Upgraded at Piper Sandler - Defense World
Cancer Vaccines Market Analysis: Growth Drivers - openPR.com
Bavarian Nordic A/S – Notice Convening Annual General Meeting - Finansavisen
HC Wainwright Reiterates “Buy” Rating for IO Biotech (NASDAQ:IOBT) - Defense World
Promising Clinical Developments and Delayed Data Boost IO Biotech’s Buy Rating - TipRanks
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, - openPR
BJ's (BJ) Q4 Earnings: What To Expect - The Globe and Mail
Dollar Retreats on Growth Risk From US Tariffs - The Globe and Mail
Metastatic Melanoma Pipeline 2024: Key Companies, MOA, ROA, - openPR
IOBT To Report Melanoma Trial Data In Q3, NPCE Eyes 15-20% Revenue Growth For 2025, DXR On Watch - RTTNews
IO Biotech on track with cancer vaccine BLA for 2025 By Investing.com - Investing.com Canada
IO Biotech on track with cancer vaccine BLA for 2025 - Investing.com India
IO Biotech Reports 2024 Business Highlights - The Manila Times
IO Biotech Reports Progress on Cylembio® Development and Upcoming FDA Submission Plans - Nasdaq
Cancer Vaccine Breakthrough? IO Biotech Accelerates Path to FDA Approval with Early Trial Completion - StockTitan
Zoom Stock: Leading the Video Market After Skype’s Exit - The Globe and Mail
The Search for the Next Keytruda: Immuno-Oncology’s Next Play - BioSpace
5 Best Biotech Stocks To Watch (March 2025) - Securities.io
IO Biotech (IOBT) to Release Quarterly Earnings on Tuesday - Defense World
United States Steel: Buy, Sell, or Hold? - The Globe and Mail
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Metastatic Melanoma Clinical Trials and Pipeline 2025: EMA, - openPR
Pre-market Movers: ISPC, TH, IVVD, TOVX... - RTTNews
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference - The Manila Times
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewswire
Artivion (AORT) Q4 Earnings: What To Expect - The Globe and Mail
Should You Buy IonQ Stock Before Feb. 26? - The Globe and Mail
IO Biotech Announces Positive Findings on TGF-β-Directed Peptide Vaccine for Solid Tumors at AACR-IO Conference - Nasdaq
Can This New Cancer Vaccine Outsmart Tumors? IO Biotech's Breakthrough Approach - StockTitan
32,667 Shares in IO Biotech, Inc. (NASDAQ:IOBT) Purchased by Vontobel Holding Ltd. - Defense World
3 Reasons to Avoid SGH and 1 Stock to Buy Instead - The Globe and Mail
IO Biotech to Present at the 45th Annual Cowen Health Care Conference - The Manila Times
Can IO Biotech's Cancer Vaccine Pipeline Transform Immunotherapy? CEO Reveals Latest Progress - Stock Titan
IO Biotech (NASDAQ:IOBT) Trading Up 4.2%Here's What Happened - MarketBeat
Head and Neck Squamous Cell Carcinoma Market Analysis 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, NDA Approval, Epidemiology and Companies by DelveInsight - Barchart
It's curtain close for Spotlight: Gene editing biotech shutters - Fierce Biotech
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):